Author Affiliations: Cincinnati Children’s Environmental Health Center, and Departments of Pediatrics and Environmental Health, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
One hundred years ago, Gibson described an epidemic of childhood lead poisoning from the ingestion of lead-based paint.1 He showed that paint was the primary source of lead intake for these children by measuring lead on wipe samples collected from porch railings and houses that had recently been painted. Gibson speculated that educational efforts would prevent lead poisoning because many children with lead poisoning were reported to bite their nails or suck their fingers.1 Four years later, after their educational efforts failed to prevent lead poisoning, Gibson’s colleague, Turner, concluded, “Prevention is easy. Paint containing lead should never be employed . . . where children, especially young children, are accustomed to play.”2
Despite these and other warnings, the United States continued to allow the use of lead-based paint until 1978.3 In contrast, many European countries banned the use of lead-based paint as early as 1909.4 The delay in banning lead-based paint in the United States was due largely to the marketing and lobbying efforts of the lead industry.3 - 4 In 1984, Mayer, then president of the Lead Industries Association, boasted, “Our victories have been in the deferral of implementation of certain regulations.”5
Prior to 1970, lead poisoning was defined by a blood lead concentration of 60 μg/dL or higher—a level often associated with overt signs or symptoms such as abdominal colic, anemia, encephalopathy, or death.6 Since then, the blood lead concentration for defining lead toxicity gradually has been reduced from 60 μg/dL to 40 μg/dL in 1971, to 30 μg/dL in 1978, and to 25 μg/dL in 1985. In 1991, the Centers for Disease Control and Prevention (CDC) further reduced the definition of undue lead exposure to a blood lead concentration of 10 μg/dL or higher.6
Over that time, children’s blood lead concentrations have declined dramatically. In the 1970s, 88% of US children younger than 6 years were estimated to have a blood lead concentration of 10 μg/dL or higher.7 When lead was at long last banned from paint in 1978 and the reduction of lead in gasoline was started in the 1970s, children’s blood lead levels began to decline almost immediately.7 By the early 1990s, fewer than 5% of children younger than 6 years were estimated to have blood lead concentrations of 10 μg/dL or higher.8
Despite the dramatic decline in children’s blood lead concentrations, lead toxicity remains a major public health problem. Environmental lead exposure in children—typically measured using lead in whole blood or teeth—has been associated with an increased risk for reading problems, school failure, delinquency, and criminal behavior.9 - 14 Moreover, there is no evidence of a threshold for the adverse consequences of lead exposure.15 - 16 Indeed, studies show that the decrements in intellectual function are, for a given increase in blood lead concentration, greater at blood lead levels lower than 10 μg/dL,15 - 16 the level considered acceptable by the CDC.
The effects of lead exposure extend beyond childhood. In adults, lead exposure—measured in bone using an x-ray fluorescence analyzer or in whole blood—has been associated with some of the most prevalent diseases of industrialized society: cardiovascular disease,17 - 19 tooth decay,20 spontaneous abortion,21 renal disease,22 cognitive decline,23 - 24 and cataracts.25 Much of the lead found in adults was deposited decades ago. Thus, regulations enacted in the 1970s were too late to prevent lead-associated morbidity and mortality for many adults.
Childhood lead toxicity is now concentrated in 2 groups: impoverished children who live in older, poorly maintained rental property and more affluent children whose families renovate older housing.26 -Â 29 From 1999 to 2001, the CDC estimated that 430Â 000 (2.2%) preschool-aged children in the United States had a blood lead concentration of 10 ÎĽg/dL or higher.30 In some cities, especially those in the Northeast and Midwest, the prevalence of children with blood lead levels exceeding 10 ÎĽg/dL is considerably higher.26 -Â 28 African American children and, to a lesser extent, Hispanic children also have significantly higher blood lead levels than white children do, even after accounting for social, behavioral, nutritional, and environmental factors.8 ,31
In 1997, the CDC shifted away from universal screening and recommended targeted blood lead screening for children who were at high risk for lead exposure.32 In 1998, the American Academy of Pediatrics issued similar recommendations.33 The rationale for targeted screening of high-risk children was to focus resources on children who would especially benefit, such as children who received Medicaid.34 Until now, there have been too few data to assess whether high-risk children who are identified as having elevated blood lead levels are being adequately tested.
In this issue of JAMA, Kemper and colleagues35 report that 46% of children who had blood lead levels indicative of lead toxicity (≥10 μg/dL) did not receive adequate follow-up testing. Although follow-up testing was better for children who had blood lead levels of 45 μg/dL or higher, 20% of these children did not receive follow-up testing. Moreover, the authors reported that children who were at highest risk for lead toxicity—urban and minority children—were the least likely to receive follow-up testing, even though 58.6% of the children had at least 1 medical encounter in the subsequent 6 months.
The problems identified by Kemper et al are only the tip of the iceberg. A child identified through screening to have an elevated blood lead level already has an elevated risk for the persistent effects of lead toxicity.9 - 16 ,36 Moreover, by 2 years of age—when children’s blood lead levels typically peak and they are consequently identified as having an elevated blood lead level—children are already growing out of their mouthing behaviors and unlikely to benefit from any environmental interventions.37 Thus, intervening only after children’s blood lead levels exceed 10 μg/dL fails to protect them from the adverse consequences of lead toxicity.38 Furthermore, as noted by Kemper et al, lead toxicity may underlie some of the prevalent health disparities found in socially disadvantaged children. Indeed, the social disparities in lead exposure may partly explain elevated rates of school failure, tooth decay, and criminal behaviors found among children in impoverished communities.10 - 14 ,20
The problem identified by Kemper et al is a symptom of a fragmented health care system, a system in which public health functions and medical care are largely divorced. Physicians are trained to provide clinic-based diagnosis and treatment. The prevention and management of common pediatric diseases with recognized environmental risk factors, such as lead poisoning, asthma, and injuries, require regulatory actions and close interactions with public health officials; the prevention of such diseases is not amenable to drug therapy or anticipatory guidance.39 -Â 40
Primary prevention of childhood lead poisoning from residential lead hazards is long overdue. Despite conclusive evidence that regulatory efforts were responsible for the dramatic decline in lead poisoning—and the early warnings by Gibson and Turner—educational efforts such as passing out brochures and mop buckets inexplicably continue to be emphasized, rather than the need for promulgation of regulations to protect children from residential lead hazards. Moreover, effective prevention interventions are typically withheld until after a child’s blood lead concentration exceeds 15 μg/dL. The key to primary prevention is to require screening of high-risk, older housing units to identify lead hazards before a child is poisoned—before occupancy and after renovation or abatement. Voluntary recommendations will inevitably fail. Screening and follow-up testing of high-risk children will remain an important part of lead poisoning prevention programs, but they should serve as a safety net, not the focus. Unfortunately, public health and housing agencies lack the resources they need to protect children from lead poisoning, and even when they do act, the study by Kemper and colleagues is a cogent reminder that it is too little, too late.
Corresponding Author: Bruce P. Lanphear, MD, MPH, Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039 (bruce.lanphear@cchmc.org).
Financial Disclosure: Dr Lanphear has served as an expert witness in the state of Rhode Island’s suit against the lead industry, on behalf of the city of Milwaukee, and the communities of Picher and Herculaneum. Dr Lanphear was not compensated for this work but Cincinnati Children’s Hospital Medical Center has been compensated for his testimony.
Editorials represent the opinions of the authors and JAMA and not those of the American Medical Association.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.